Belvedere Trading Reduces $50K in Arbutus Biopharma Corporation ($ABUS)
Key Points
- Belvedere Trading changed its Arbutus Biopharma Corporation ($ABUS) stake by 100% last quarter, cutting to 0 shares.
- $ABUS last traded around $4.70.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Belvedere Trading reduced its position in Arbutus Biopharma Corporation ($ABUS), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Arbutus Biopharma Corporation after selling 10,721 shares during the quarter.
Arbutus Biopharma Corporation Stock Down 7.4%
Shares of Arbutus Biopharma Corporation ($ABUS) traded around $4.70 on Saturday, down 7.4% for the day.
Arbutus Biopharma Corporation Earnings
Analysts Set New Price Targets
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Get Arbutus Biopharma Corporation alerts
New 13F filings, insider trades, and analyst moves on $ABUS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.